Asapiprant (BGE-175) is an oral, small molecule, anti-inflammatory drug that acts as a selective prostaglandin D2 receptor 1 (DP1) antagonist.
May 19 2022 |
et al., NCT04705597 | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study to Investigate the Efficacy and Safety of BGE-175 in Hospitalized Adults With COVID-19 |
| 63% higher mortality (p=0.21), 32% higher ICU admission (p=0.37), 24% higher severe cases (p=0.36), and 33% slower improvement (p=0.17). RCT 194 hospitalized COVID-19 patients showing no significant differences with asapiprant (BGE-175). | ||
Please send us corrections, updates, or comments.
c19early involves the extraction of 200,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. IMA and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.